Epilepsy drug may increase risk of autism in children

Dec 01, 2008

A new study shows that women who take the epilepsy drug valproate while pregnant may significantly increase their child's risk of developing autism. The preliminary research is published in the December 2, 2008, print issue of Neurology, the medical journal of the American Academy of Neurology.

The ongoing study involves 632 children, nearly half of whom were exposed to epilepsy drugs during gestation. Of the children whose mothers took epilepsy drugs while pregnant, 64 were exposed to valproate, 44 to lamotrigine, 76 to carbamazepine and 65 to other epilepsy drugs. Of the 632 children in the study, nine have been diagnosed with autism and one has shown symptoms of the disorder. The children were tested at one, three and six years old. Two-thirds of the children were six years old by the end of the study.

The study found seven of the children with autism had mothers who took an epilepsy drug while pregnant, four of those children were exposed to valproate while a fifth child's mother took a combination of valproate and lamotrigine. The children whose mothers were given valproate during pregnancy were seven times more likely to develop autism compared to children whose mothers did not take an epilepsy drug while pregnant. This risk was not seen with the other epilepsy drugs. None of the children in the study had any known family history of autism.

"The potential risk for autism in this study was substantial for children whose mothers took valproate while pregnant, but more research needs to be done since these are early findings," says study author Gus Baker, PhD, FBPsS, of the University of Liverpool in the United Kingdom."However, women who take valproate while pregnant should be informed of the possible risks of autism and are encouraged to discuss them with their doctor. Those who are taking valproate should not stop their treatment without speaking to their doctor first."

Other studies have shown that valproate is more likely to cause birth defects than other epilepsy drugs.

Symptoms of autism include difficulty in language development, a lack of attention, social problems and the inability to understand other people's feelings.

Source: American Academy of Neurology

Explore further: Determine patient preferences by means of conjoint analysis

add to favorites email to friend print save as pdf

Related Stories

Sapphire talk enlivens guesswork over iPhone 6

4 hours ago

Sapphire screens for the next iPhone? Sapphire is second only to diamond in hardness scratch-proof properties, used in making LEDs, missiles sensors, and on screens for luxury-tier phones. Last year, the ...

The source of the sky's X-ray glow

7 hours ago

In findings that help astrophysicists understand our corner of the galaxy, an international research team has shown that the soft X-ray glow blanketing the sky comes from both inside and outside the solar system.

Recommended for you

Determine patient preferences by means of conjoint analysis

18 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 3

Adjust slider to filter visible comments by rank

Display comments: newest first

Bbrhuft
not rated yet Dec 01, 2008
It has been known since 1980 that valproate can cause Fetal Valproate Syndrome and in 1994 autism (Valproate-induced autism), indeed valproate is fed to female mice and rat's in order to study how the disruption of brain growth during gestation causes autism.
edwards
not rated yet Dec 02, 2008
WhoCanWeSue.com?
gryfonclaw
not rated yet Jan 07, 2009
Not to mention valproate is almost useless- only slightly better than placebo.